


Amendments to the Claims:

This listing of claims replaces all prior versions, and listings, of claims in the captioned application.

Listing of the Claims:

1-16. (Cancelled).

17. (Currently Amended) A compound of formula (I),



the *N*-oxide forms, the addition salts and the stereo-chemically isomeric forms thereof, wherein

n is 0, 1 or 2;

X is N or CR⁷, wherein R⁷ is hydrogen or taken together with R¹ may form a bivalent radical of formula $-CH=CH-CH=CH-$;

R¹ is C₁₋₆alkyl or thiophenyl;

R² is hydrogen, hydroxy, C₁₋₆alkyl, or C₃₋₆alkynyl or taken together with R³ may form $=O$;

except that when X is N, R² together with R³ cannot form $=O$;

R³ is a radical selected from



wherein

s is 0, 1, 2 or 3;

R⁸, R¹⁰ and R¹¹ are each independently selected from $-CHO$, C₁₋₆alkyl,

hydroxyC₁₋₆alkyl, C₁₋₆alkylcarbonyl, amino, C₁₋₆alkylamino,
di(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkyloxycarbonyl, C₁₋₆alkylcarbonylaminoC₁₋₆alkyl,
piperidinylC₁₋₆alkylaminocarbonyl, piperidinyl, piperidinylC₁₋₆alkyl,
piperidinylC₁₋₆alkylaminocarbonyl, C₁₋₆alkyloxy, thiophenylC₁₋₆alkyl,
pyrrolylC₁₋₆alkyl, arylC₁₋₆alkylpiperidinyl, arylcarbonylC₁₋₆alkyl,
arylcarbonylpiperidinylC₁₋₆alkyl, haloindazolylpiperidinylC₁₋₆alkyl,
arylC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl, and

R⁹ is hydrogen or C₁₋₆alkyl;




or R³ is a group of formula




wherein

t is 0, 1, 2 or 3;

-Z is a heterocyclic ring system selected from



wherein R¹² is hydrogen, halo, C₁₋₆alkyl, aminocarbonyl, amino, hydroxy, aryl,




C₁₋₆alkylaminoC₁₋₆alkyloxy, C₁₋₆alkyloxyC₁₋₆alkyl, C₁₋₆alkyloxyC₁₋₆alkylamino, arylC₁₋₆alkyl, di(phenylC₂₋₆alkenyl), piperidinyl, piperidinylC₁₋₆alkyl, C₃₋₁₀cycloalkyl, C₃₋₁₀cycloalkylC₁₋₆alkyl, aryloxy(hydroxy)C₁₋₆alkyl, haloindazolyl, arylC₁₋₆alkyl, arylC₂₋₆alkenyl, arylC₁₋₆alkylamino, morpholino, C₁₋₆alkylimidazolyl, pyridinylC₁₋₆alkylamino; and

R¹³ is hydrogen, piperidinyl or aryl;

R⁴, R⁵ and R⁶ are each independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy, C₁₋₆alkyl, C₁₋₆alkyloxy, amino, aminoC₁₋₆alkyl, di(C₁₋₆alkyl)amino, di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy or C₁₋₆alkyloxycarbonyl, or C₁₋₆alkyl substituted with 1, 2 or 3 substituents independently selected from hydroxy, C₁₋₆alkyloxy, or aminoC₁₋₆alkyloxy; or

when R⁵ and R⁶ are on adjacent positions they may taken together form a bivalent radical of formula




wherein R¹⁴ is C₁₋₆alkyl;

and aryl is phenyl, phenyl substituted with halo, C₁₋₆alkyl or C₁₋₆alkyloxy.

18. (Currently Amended) A compound as claimed in claim 17 wherein

R⁺ is C₁₋₆alkyl; R³ is a radical selected from the group consisting of (a-1), (a-2), (a-3) (a-5), and (b-1) wherein -Z is a heterocyclic ring system selected from (c-1), (c-6), (c-8), (c-9), or (c-11); s is 0, 1 or 2; R⁸ and R¹⁰ are each independently selected from -CHO, C₁₋₆alkyl, hydroxyC₁₋₆alkyl, di(C₁₋₆alkyl)aminoC₁₋₆alkyl, C₁₋₆alkylcarbonylaminoC₁₋₆alkyl, piperidinylC₁₋₆alkyl,


piperidinylC₁₋₆alkylaminocarbonyl, C₁₋₆alkyloxy, thiophenylC₁₋₆alkyl,
 pyrrolylC₁₋₆alkyl, arylC₁₋₆alkylpiperidinyl, arylcarbonylC₁₋₆alkyl,
 arylcarbonylpiperidinylC₁₋₆alkyl, haloindazolylpiperidinylC₁₋₆alkyl, or
 arylC₁₋₆alkyl(C₁₋₆alkyl)aminoC₁₋₆alkyl; t is 0 or 2; R¹² is hydrogen,




C₁₋₆alkyl, aminocarbonyl, C₁₋₆alkyloxyC₁₋₆alkylamino,
 di(phenylC₂₋₆alkenyl), piperidinylC₁₋₆alkyl, C₃₋₁₀cycloalkyl,
 C₃₋₁₀cycloalkyl(C₁₋₆alkyl, haloindazolyl, or arylC₂₋₆alkenyl); R⁴, R⁵ and R⁶ are each
 independently selected from hydrogen, halo, trihalomethyl, trihalomethoxy,
 C₁₋₆alkyl, C₁₋₆alkyloxy, di(C₁₋₆alkyl)amino, di(C₁₋₆alkyl)aminoC₁₋₆alkyloxy or
 C₁₋₆alkyloxycarbonyl; and when R⁵ and R⁶ are on adjacent positions they may taken
 together form a bivalent radical of formula (d-1) or (d-2).

19. (Currently Amended) A compound according to claim 17 wherein
 n is 0; X is CH; R¹ is C₁₋₆alkyl; R² is hydrogen; wherein -Z is a heterocyclic ring
 system selected from (c-1); t is 2; R¹² is hydrogen; R¹³ is hydrogen; and R⁵ and R⁶ are
 on adjacent positions and taken together form a bivalent radical of formula (d-2).


20. (Currently Amended) A compound selected from the group consisting of compounds
 No 16, compound No 144, and compound No. 145:



compound 16



Compound 144



Compound 145

21. (Previously Presented) A pharmaceutical composition comprising pharmaceutically acceptable carriers and as an active ingredient a therapeutically effective amount of a compound as claimed in claim 17.

22. (Cancelled).